Updated linvoseltamab data showcase continued deepening of responses in patients with heavily pre-treated multiple myeloma

At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an eha oral presentation and simultaneously published in the journal of clinical oncology

REGN Ratings Summary

Quant